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Idiopathic Interstitial Pneumonia with Increased Serum Levels of Cancer-
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Naoto Burioka, Hisashi Suyama, Toshiyuki Tatsukawa, Shinji Hori, Yasushi
Kometani, Yuji Kawasaki, Noriko Nakada and Takao Sasaki
Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago 683,
Japan
We report a case of idiopathic interstitial pneumonia (IIP) with elevated serum levels
of carbohydrate antigen 19-9 (CA19-9) and sialyl Lewisx-i (SLX).  A 67-year-old Japa-
nese woman was admitted to our hospital with a fever, dry cough and dyspnea on exer-
tion.  She had previously been admitted and had then been diagnosed as IIP.  The
serum level of SLX, measured by radioimmunoassay (RIA), was markedly elevated
(120 U/mL; cut-off, < 38 U/mL).  The serum level of CA19-9, measured by RIA, was at
a slightly high level (46 U/mL; cut-off, < 40 U/mL).  The values of CA19-9 and SLX
were changed during her clinical course.  These cancer-associated antigens were im-
munohistochemically expressed on the hyperplastic bronchiolar epithelium, on the sur-
face epithelium cells of microscopic honeycombing and on exudates in air space.  Repeat-
ed damage to the lungs may have forced these antigens of the markers into the blood
circulation, which may have resulted in the elevated serum levels of CA19-9 and SLX
observed in this patient.
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Abbreviations:  CA19-9, carbohydrate antigen 19-9; CRP, C-reactive protein; DBP, diffuse panbronchiolitis;
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The cancer-associated antigens, carbohydrate
antigen 19-9 (CA19-9) (Koprowski et al., 1979)
and sialyl Lewisx-i (SLX) (Fukushima et al.,
1984), have been used as markers in the diagno-
sis of adenocarcinoma (Del Villano et al., 1983;
Chia et al., 1985).  Serum CA19-9 and SLX are,
however, frequently elevated in patients with
benign respiratory disease, such as cystic fibro-
sis (Frates et al., 1989; Wu et al., 1992), inter-
stitial pneumonia (Bungo et al., 1988; Mukae et
al., 1991), diffuse panbronchiolitis (DPB)
(Noguchi et al., 1989; Mukae et al., 1993) and
bronchiectasis (Burioka et al., 1995).  We treat-
ed a female patient with idiopathic interstitial
pneumonia (IIP) who had elevated serum levels
of CA19-9 and SLX.  We examined the serum
levels of these tumor markers and the immuno-
histochemistry during her clinical course.
Case Report
A 67-year-old Japanese woman was admitted to
our hospital in August 1995 with a fever, dry
cough and dyspnea on exertion.  She had pre-
viously been admitted because of an abnormal-
ity observed on a chest radiograph in January
1992. The diagnosis at that time was IIP.  The
patient had not received corticosteroid therapy.
Physical examination during present admis-
sion revealed fine cracking lung sounds and
cyanosis.  Her temperature was 38˚C.  The labo-
ratory examination revealed the following:
leukocyte count, 8400/mm3; a high level of
lactic acid dehydrogenase (LDH, 307 IU/L,
normal range, 100–225 IU/L); a high level of C-
reactive protein (CRP), 3.6 mg/dL; and a high
level of erythrocyte sedimentation rate (ESR),
122 mm/h.  Serum levels of immunoglobulin G
(3477 mg/dL), immunoglobulin A (481 mg/dL)
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tient was administered antibiotics at that time.
Nevertheless, her symptoms and hypoxemia did
not improve.  Because of the worsened condi-
tion of IIP, the patient was administered pred-
nisolone (60 mg/day) intravenously in Septem-
ber 1995.  An improvement in the PaO2 (53
mmHg) of room air breathing was recognized.
Reduction in the following parameters were
noted:  serum LDH (241 IU/L), ESR (28 mm/
h), serum level of SLX (74 U/mL), and serum
level of CA19-9 (21.4 U/mL) in October 1995.
After an intravenous administration of methyl-
prednisolone in November 1995, a respiratory
infection was diagnosed.  Cough and dyspnea
on exertion were worsened.  Oral cyclophos-
phamide (50 mg/day) was added to the regimen.
The patient’s condition deteriorated in February
1996; serum levels of LDH (389 IU/L), SLX
(110 U/mL), and CA19-9 (94.3 U/mL) were
again elevated.  Mechanical ventilation was
instituted, but the patient died in February 1996.
There was a significant single linear correlation
between the serum level of LDH and that of
CA19-9 during this patient’s clinical course
(Fig. 2).  However, there was no significant cor-
relation between the serum level of LDH and
that of SLX.
≈
and immunoglobulin M (320
mg/dL) were all elevated.
Tests for anti-nuclear anti-
body and anti-DNA antibody
were negative.  A test for anti-
body against hepatitis C virus
or human T-cell lymphotropic
virus type I was negative.
Mycobacterium in sputum cul-
ture was negative.  Arterial
blood gas analysis after breath-
ing room air showed severe
hypoxemia (PaO2; 34 mmHg).
The serum level of SLX, mea-
sured by radioimmunoassay
(RIA), was markedly elevated
(120 U/mL; cut-off, < 38 U/
mL) and the serum level of
CA19-9, measured by RIA,
was slightly elevated (46 U/
mL; cut-off, < 40 U/mL).  The
chest radiograph on admission
showed reticular, small patches of infiltrate.
Computed tomography of the chest demon-
strated bilateral diffuse reticulo-nodular shadows
in the lung fields.  Gynecological examination
and computed tomographic images of the head
and abdomen revealed no malignancy.
The patient’s clinical course is summarized
in Fig. 1.  The IIP appeared to have been aggra-
vated by infection in August 1995.  So, the pa-
Fig. 2.  Single linear correlation between the serum
level of LDH and that of CA19-9 during this
patient's clinical course.  A significant correlation
was observed (r = 0.891; P < 0.003).
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Fig. 1.  Clinical course.  , ESR; , LDH; , SLX;  , CA19-9.
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Fig. 3.  Light microscopy showed a dilatation of the bron-
chioles, a hyperplastic epithelium, severe fibrosis of the
pulmonary parenchyma, anthracosis and infiltration of
inflammatory cells (hematoxylin and eosin stain, × 30).
Fig. 4.  a, b: Transbronchial lung biopsy speci-
men in January 1992. c, d: Necropsy specimen in
February 1996.
a: Immunohistochemical staining with anti-
CA19-9 monoclonal antibody showed negative
reaction for CA19-9 (× 100).  b: Immunohisto-
chemical staining with anti-SLX monoclonal
antibody showed positive reaction for SLX on the
bronchiolar surface epithelium (× 100).  Immuno-
histochemical staining with anti-CA19-9 and
anti-SLX monoclonal antibodies showed strongly
positive reactions for both CA19-9 (c) and SLX
(d) on the hyperplastic bronchiolar epithelium, on
the flattened and cuboidal metaplastic epithelial
cells of microscopic honeycoming and on exu-
dates in the air spaces (× 100).
Pathological findings
Specimens of tissue from the respiratory
tract were obtained at necropsy.  The lung
exhibited a gross honeycomb appearance.
Light microscopy showed dilatation of the
bronchioles, a hyperplastic epithelium,
severe fibrosis of the pulmonary parenchy-
ma, anthracosis and infiltration of inflam-
matory cells (Fig. 3).
Immunohistochemical staining with anti-
CA19-9 monoclonal antibody (1116-NS-19-
9, TFB, Tokyo, Japan) showed negative re-
action for CA19-9 on the lung specimen in
January 1992 (Fig. 4a).  Immunohisto-
chemical staining with anti-SLX monoclonal
antibody (Anti KM-93, Kyowa Medex,
Tokyo) showed a positive reaction on the
bronchiolar surface epithelium of the lung
specimen in January 1992 (Fig. 4b).  As for
the necropsy specimen in February 1996,
immunohistochemical staining with anti-
CA19-9 and anti-SLX monoclonal anti-
bodies showed strongly positive reactions
for both CA19-9 and SLX on the hyperplas-
tic bronchiolar epithelium, on the flattened
and cuboidal metaplastic epithelial cells of
microscopic honeycoming and on exudates in
the air spaces (Figs. 4c and d).  No malignant
findings were recognized in the specimen of
the patient’s lung.
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Discussion
When the patient had only a slightly dry cough
with slight abnormalities on the chest radio-
graph in January 1992, the serum levels of
CA19-9 and SLX were within the normal range
(Fig. 1).  To verify whether CA19-9 and SLX
were produced in the lungs, we examined im-
munohistochemically their localization in the
lungs of this patient by an enzyme-labeled anti-
body method (Figs. 4a–d).  In her deteriorating
condition in August 1995, the serum levels of
CA19-9 and SLX were both elevated (Fig. 1).
As IIP worsens, these cancer-associated antigens
are increasingly expressed on the surface of the
bronchiolar epithelium and on the flattened and
cuboidal metaplastic epithelial cells of
microscopic honeycoming (Figs. 4c and d).
CA19-9 is synthesized, to some degree, by the
normal epithelial cells and respiratory glands of
the airway (Atkinson et al., 1982; Matsuoka et
al., 1990; Takayama et al., 1990), and SLX is
also synthesized, to some degree, by the
epithelial cells of the normal airway (Shiota et
al., 1989) in healthy subjects.  These sialylated
glycoprotein tumor markers are immuno-
histochemically expressed in the mucus cells of
bronchial hyperplastic glands and in the surface
epithelium cells in patients with benign pul-
monary diseases by inflammation (Noguchi et
al., 1989; Mukae et al., 1991; Burioka et al.,
1995).  However, it has been unclear why these
cancer-associated antigens are expressed on the
lung tissue of patients with IIP.  Repeated
damage to the lungs may have forced these
antigens of the markers into the circulation
(Noguchi et al., 1989; Mukae et al., 1991;
Mukae et al., 1993; Burioka et al., 1995), which
resulted in elevated serum levels of CA19-9 and
SLX in this patient.  The serum level of SLX
was within the normal range despite expression
of SLX on the lung tissue in January 1992 (Fig.
2b).  The destruction of the lung might be little
at that time.
There was a significant correlation between
the serum level of LDH and that of CA19-9
during this patient's clinical course. The serum
level of LDH reportedly reflects damage to the
lungs in interstitial pneumonia (De Remee,
1968).  However, the serum level of LDH did
not parallel the serum level of CA19-9 during
December 1995 and January 1996. Although
the mechanism is unclear, the expression of
CA19-9 on the lung tissue might have been
suppressed in January 1996.  Treatment with a
corticosteroid led to improvements in clinical
symptoms and also led to reductions in serum
levels of CA19-9, SLX, ESR and LDH.  This
finding seems to indicate that the administra-
tion of a corticosteroid transiently inhibited the
exacerbation of IIP.  When a high serum level
of CA19-9 is recognized in IIP patients, the
possibility remains that an examination of the
correlation between serum values of LDH and
CA19-9 during the clinical course may be bene-
ficial to distinguish some IIP patients who had
no malignant findings from the patients with
adenocarcinoma.
Further study is needed to investigate why
cancer-associated antigens are expressed in the
lung tissue of the patient with IIP.
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